Tata 1mg turns EBITDA positive across ePharmacy, diagnostics, D2C in Q4 FY26
Tata 1mg hit EBITDA breakeven across all core verticals in Q4 FY26. Diagnostics crossed Rs 600 Cr ARR with 40% YoY growth across 19 NABL labs in 70 cities. D2C surpassed Rs 200 Cr ARR with 65% specialty pharma growth. Offline footprint at 280 stores, targeting 500+ within 12 months.
Tata 1mg turned EBITDA positive across all core verticals in Q4 FY26. ePharmacy hit breakeven, diagnostics crossed Rs 600 Cr ARR, D2C surpassed Rs 200 Cr ARR. Retail footprint at 280 stores, targeting 500+ within 12 months.